Fundamental Considerations of Targeted Drug Therapies for Breast Cancer
Breast cancer is a complex disease for which pharmacological treatment does not guarantee success or cure. In addition, current pharmacological therapies induce unwanted side effects due to their lack of specificity or selectivity. Therefore, it is necessary to develop new therapeutic options to imp...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-10-01
|
| Series: | Future Pharmacology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-9879/3/4/43 |
| _version_ | 1797380957414621184 |
|---|---|
| author | Ileana Castillo-Tobías Lia Berlanga Joan Poblano María del C. Rodríguez-Salazar Hilda Aguayo-Morales Luis E. Cobos-Puc |
| author_facet | Ileana Castillo-Tobías Lia Berlanga Joan Poblano María del C. Rodríguez-Salazar Hilda Aguayo-Morales Luis E. Cobos-Puc |
| author_sort | Ileana Castillo-Tobías |
| collection | DOAJ |
| description | Breast cancer is a complex disease for which pharmacological treatment does not guarantee success or cure. In addition, current pharmacological therapies induce unwanted side effects due to their lack of specificity or selectivity. Therefore, it is necessary to develop new therapeutic options to improve these aspects. Currently, phytochemicals with antineoplastic properties have been identified from a wide variety of plant sources, and new therapeutic options have been developed based on the conjugation of drugs with polymeric matrices, resulting in nanoparticles or hydrogels with improved properties. Some antineoplastic drugs have been conjugated with antibodies to improve their selectivity and specificity. One of the most important advances in the treatment of breast cancer has been the development of cyclin inhibitors and gene therapy. This review provides an overview of drugs derived from medicinal plants and polymeric matrices with high potential for use in the treatment of breast cancer. We also highlight the clinical evidence for the use of anti-HER2 monoclonal antibodies and cyclin inhibitors in breast cancer, as well as the advantages of using conjugated antibodies. Finally, we mention some considerations that should be taken into account in the search for new therapeutic agents from phytochemicals, polymers, antibodies, cyclin inhibitors, and gene therapy focused on the treatment of breast cancer. |
| first_indexed | 2024-03-08T20:44:27Z |
| format | Article |
| id | doaj.art-1770a923e4334f67a50ce7203ad2159e |
| institution | Directory Open Access Journal |
| issn | 2673-9879 |
| language | English |
| last_indexed | 2024-03-08T20:44:27Z |
| publishDate | 2023-10-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Future Pharmacology |
| spelling | doaj.art-1770a923e4334f67a50ce7203ad2159e2023-12-22T14:10:15ZengMDPI AGFuture Pharmacology2673-98792023-10-013468670710.3390/futurepharmacol3040043Fundamental Considerations of Targeted Drug Therapies for Breast CancerIleana Castillo-Tobías0Lia Berlanga1Joan Poblano2María del C. Rodríguez-Salazar3Hilda Aguayo-Morales4Luis E. Cobos-Puc5Facultad de Ciencias Químicas, Unidad Saltillo, Universidad Autónoma de Coahuila, Boulevard Venustiano Carranza S/N Esquina con Ing. José Cárdenas Valdés, República Oriente, Saltillo 25290, Coahuila, MexicoFacultad de Ciencias Químicas, Unidad Saltillo, Universidad Autónoma de Coahuila, Boulevard Venustiano Carranza S/N Esquina con Ing. José Cárdenas Valdés, República Oriente, Saltillo 25290, Coahuila, MexicoFacultad de Ciencias Químicas, Unidad Saltillo, Universidad Autónoma de Coahuila, Boulevard Venustiano Carranza S/N Esquina con Ing. José Cárdenas Valdés, República Oriente, Saltillo 25290, Coahuila, MexicoFacultad de Ciencias Químicas, Unidad Saltillo, Universidad Autónoma de Coahuila, Boulevard Venustiano Carranza S/N Esquina con Ing. José Cárdenas Valdés, República Oriente, Saltillo 25290, Coahuila, MexicoFacultad de Ciencias Químicas, Unidad Saltillo, Universidad Autónoma de Coahuila, Boulevard Venustiano Carranza S/N Esquina con Ing. José Cárdenas Valdés, República Oriente, Saltillo 25290, Coahuila, MexicoFacultad de Ciencias Químicas, Unidad Saltillo, Universidad Autónoma de Coahuila, Boulevard Venustiano Carranza S/N Esquina con Ing. José Cárdenas Valdés, República Oriente, Saltillo 25290, Coahuila, MexicoBreast cancer is a complex disease for which pharmacological treatment does not guarantee success or cure. In addition, current pharmacological therapies induce unwanted side effects due to their lack of specificity or selectivity. Therefore, it is necessary to develop new therapeutic options to improve these aspects. Currently, phytochemicals with antineoplastic properties have been identified from a wide variety of plant sources, and new therapeutic options have been developed based on the conjugation of drugs with polymeric matrices, resulting in nanoparticles or hydrogels with improved properties. Some antineoplastic drugs have been conjugated with antibodies to improve their selectivity and specificity. One of the most important advances in the treatment of breast cancer has been the development of cyclin inhibitors and gene therapy. This review provides an overview of drugs derived from medicinal plants and polymeric matrices with high potential for use in the treatment of breast cancer. We also highlight the clinical evidence for the use of anti-HER2 monoclonal antibodies and cyclin inhibitors in breast cancer, as well as the advantages of using conjugated antibodies. Finally, we mention some considerations that should be taken into account in the search for new therapeutic agents from phytochemicals, polymers, antibodies, cyclin inhibitors, and gene therapy focused on the treatment of breast cancer.https://www.mdpi.com/2673-9879/3/4/43breast cancerphytochemicalspolymersmonoclonal antibodycyclin inhibitorsgene therapy |
| spellingShingle | Ileana Castillo-Tobías Lia Berlanga Joan Poblano María del C. Rodríguez-Salazar Hilda Aguayo-Morales Luis E. Cobos-Puc Fundamental Considerations of Targeted Drug Therapies for Breast Cancer Future Pharmacology breast cancer phytochemicals polymers monoclonal antibody cyclin inhibitors gene therapy |
| title | Fundamental Considerations of Targeted Drug Therapies for Breast Cancer |
| title_full | Fundamental Considerations of Targeted Drug Therapies for Breast Cancer |
| title_fullStr | Fundamental Considerations of Targeted Drug Therapies for Breast Cancer |
| title_full_unstemmed | Fundamental Considerations of Targeted Drug Therapies for Breast Cancer |
| title_short | Fundamental Considerations of Targeted Drug Therapies for Breast Cancer |
| title_sort | fundamental considerations of targeted drug therapies for breast cancer |
| topic | breast cancer phytochemicals polymers monoclonal antibody cyclin inhibitors gene therapy |
| url | https://www.mdpi.com/2673-9879/3/4/43 |
| work_keys_str_mv | AT ileanacastillotobias fundamentalconsiderationsoftargeteddrugtherapiesforbreastcancer AT liaberlanga fundamentalconsiderationsoftargeteddrugtherapiesforbreastcancer AT joanpoblano fundamentalconsiderationsoftargeteddrugtherapiesforbreastcancer AT mariadelcrodriguezsalazar fundamentalconsiderationsoftargeteddrugtherapiesforbreastcancer AT hildaaguayomorales fundamentalconsiderationsoftargeteddrugtherapiesforbreastcancer AT luisecobospuc fundamentalconsiderationsoftargeteddrugtherapiesforbreastcancer |